European Pharmaceutical Review

AUGUST 17, 2023

Recent EU approval means adults who have four or more migraine days per month can now access the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant). This was compared to 27 percent of patients in the placebo arm. This result was compared to 29 percent of participants given placebo.

Hospitals 83

Hospitals 83

Pharmaceutical Technology

JUNE 1, 2023

The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Pfizer ’s rimegepant (Vydura) to prevent migraine attacks. NICE medicines evaluation director Helen Knight said: “Each year, the lives of millions of people in England are blighted by migraine attacks.

98

98

European Pharmaceutical Review

JUNE 1, 2023

An oral treatment for preventing migraines has been recommended by the National Institute for Health and Care Excellence (NICE) for the first time. Rimegepant (Vydura) is recommended as an option for episodic migraine in adults after having at least three previous failed preventive treatments. How does the oral migraine treatment work?

86

86

Hospital Pharmacy Europe

SEPTEMBER 14, 2023

NICE has approved rimegepant (brand name Vydura) as the first treatment for acute migraine, in draft guidance published today (14 September). It prevents the release of calcitonin gene-related peptide thought to be responsible for the severe pain associated with migraine attacks. NICE put the cost of the drug at £12.90

Hospitals 59

Hospitals 59

Pharmaceutical Technology

MARCH 10, 2023

The US Food and Drug Administration (FDA) has granted approval for Pfizer ’s Zavzpret (zavegepant) for the acute treatment of migraine in adult patients with or without aura. Zavzpret is claimed to be the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray approved to treat migraine.

FDA 98

FDA 98

The Checkup by Singlecare

APRIL 4, 2024

Food and Drug Administration (FDA) used to treat and prevent migraine headaches. Migraine attacks are associated with raised levels of a protein called CGRP in the brain, and Nurtec works by blocking CGRP receptors from being activated. As a result, people can experience pain relief and improved migraine symptoms.

Dosage 40

Dosage FDA 40

PharmaShots

JUNE 22, 2023

The results showed no statistical difference b/w women with migraine who used the device during pregnancy throughout 3mos. The device is a safe treatment for migraine during pregnancy, not increasing the risk for adverse pregnancy outcomes. postpartum, and for those who did not use during this period, 66.7% achieved pain relief @2hrs.

40

40

Hospital Pharmacy Europe

FEBRUARY 24, 2023

In a recent phase 2/3 trial, oral rimegepant, when taken every other day, was found to be effective as a preventive treatment of migraine, with its tolerability similar to placebo. It was proposed by the manufacturer that rimegepant is used for acute migraine treatment in patients who have failed to respond to two or more triptans.

Documentation 96

Documentation Hospitals 96

The Checkup by Singlecare

MARCH 17, 2023

Food and Drug Administration approved Zavzpret, the first calcitonin gene-related peptide (CGRP) antagonist nasal spray to treat acute migraine (with or without aura) in adults. who experience migraine. Manufactured by Pfizer, Zavzpret (zavegepant) is a fas t-acting medication shown in Phase 3 clinical trials to have broad efficacy.

FDA 98

FDA Insurance Coverage Insurance 98

The Checkup by Singlecare

MARCH 8, 2024

Compare Aimovig alternatives | Beta blockers | Antidepressants | Anticonvulsants | Calcium channel blockers | Other CGRP receptor antagonists | Natural alternatives | How to switch meds Aimovig is an injectable drug approved to help prevent migraine headaches. Nausea, light sensitivity, and sound sensitivity typically accompany migraines.

Labelling 52

Labelling Insurance Insurance Coverage Dosage 52

Pharmacy Times

DECEMBER 7, 2023

Amanda Hickman, PharmD, MPH, MSCS, discusses the clinical assessment to lower migraines (CALM) in an HSSP setting.

Specialty Pharmacies 65

Specialty Pharmacies 65

Pharmafile

SEPTEMBER 5, 2023

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), for the prophylaxis of migraine in adult patients who have had at least four migraine days each month.

64

64

The Checkup by Singlecare

NOVEMBER 18, 2022

Before the first migraine-specific drugs hit the pharmaceutical market in 2018, the medications used to treat migraine were meant for other health conditions. Antidepressants, beta blockers, and epilepsy drugs reduced migraine symptoms in many people, but no one knew for sure how or why. Here’s what you need to know.

98

98

The Checkup by Singlecare

DECEMBER 11, 2023

Migraine headache Migraine headaches affect about 10% of the population. What distinguishes migraines from other types of headaches is that they tend to be a full-body experience: head pain and pressure are usually one of several symptoms. A tension headache is a primary headache that occurs without an underlying cause.

105

105

Pharmaceutical Technology

OCTOBER 4, 2022

A CGRP receptor antagonist, NURTEC ODT is approved by the US Food and Drug Administration (FDA) for use in adults for acute treatment of migraine irrespective of aura status as well as for preventive episodic migraine treatment. It is also approved in the EU under the trade name Vydura for use in similar indications.

FDA 106

FDA 106

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has accepted Satsuma Pharmaceuticals’ 505(b)(2) new drug application (NDA) for STS101 for acute treatment of migraine, for review. It provides significant benefits compared to the current acute treatments for migraine.

FDA 59

FDA Labelling 59

The Checkup by Singlecare

JANUARY 2, 2024

“Dehydration headache most often has the appearance of a tension-type headache,” says Eric Baron, DO , a neurologist at the Cleveland Clinic Center for Neurological Restoration – Headache and Chronic Pain Medicine, in Cleveland. One thing that is clear: Dehydration makes headaches worse.

105

105

The Checkup by Singlecare

DECEMBER 27, 2023

Migraines can be debilitating, and they affect more than 1 billion people globally. Fioricet ( butalbital-APAP-caffeine ) is a combination medication used to treat tension headaches, but it may also be prescribed for migraines. How does Fioricet treat migraine headaches? Caffeine is a natural CNS stimulant that boosts alertness.

Mayo Clinic 52

Mayo Clinic Dosage FDA 52

Pharmaceutical Technology

NOVEMBER 18, 2023

LuAG-09222 is under clinical development by H. Lundbeck and currently in Phase II for Migraine.

52

52

Pharmaceutical Technology

FEBRUARY 8, 2024

Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Migraine.

40

40

Hospital Pharmacy Europe

DECEMBER 19, 2022

The presence of enlarged perivascular spaces in the brains of migraine patients may indicate the presence of glymphatic disruption. Migraine is a common headache-related condition that affects an estimated 12% of the population. Enlarged perivascular spaces in migraine and control patients.

Hospitals 52

Hospitals 52

The Checkup by Singlecare

DECEMBER 13, 2023

Headache behind eyes The most common types of headaches behind the eyes are cluster headaches, migraine headaches, and sinus headaches, according to Dr. Reddy. Cluster headaches and migraines tend to cause severe pain on just one side of your head, while sinus headaches can develop on one or both sides. Reddy and Natbony.

Hospitals 52

Hospitals 52

pharmaphorum

JANUARY 28, 2021

New findings from a digital study have challenged the belief that stress is a significant factor in triggering migraine attacks. At the same time 76% of the total number of migraine attacks were associated with either flat or decreasing levels of perceived stress.

Data Entry 105

Data Entry 105

The Checkup by Singlecare

DECEMBER 27, 2023

Common causes of a headache on top of the head include tension, nerve inflammation, migraine, and dehydration. Migraine headaches Migraine is a headache disorder that causes moderate to severe pain. For example, a headache on the top of the head often feels like a heavy weight or a tightness on or around the top of the skull.

Mayo Clinic 52

Mayo Clinic 52

Hospital Pharmacy Europe

MARCH 15, 2023

Zavegepant represents the first, non-oral calcitonin gene-related peptide receptor antagonist approved for the treatment of acute migraine In a press release, manufacturer Pfizer has announced that zavegepant has become the first calcitonin gene-related peptide receptor antagonist to receive approval by the FDA for the management of acute migraine.

Adverse Reactions 52

Adverse Reactions Hospitals FDA 52

Hospital Pharmacy Europe

NOVEMBER 1, 2022

Since 2006, he has been working on migraine and, in particular, experimental models of migraine. Professor Ashina’s research focuses on experimental models of migraine in humans. How would you define migraine and what are the main symptoms? How is migraine classified?

Communication 52

Communication Hospitals 52

The Checkup by Singlecare

DECEMBER 27, 2023

In fact, a lack of sleep is a known trigger for migraine and other types of headaches, too. Research suggests that poor sleep quality directly affects the severity and frequency of migraine and tension headaches. This disruption can lead to certain types of headaches, including migraines and cluster headaches.

59

59

Pharmaceutical Technology

JULY 19, 2022

AbbVie has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its atogepant for prophylaxis of migraine in adults who experience a minimum of four migraine days each month. An oral CGRP receptor antagonist (gepant), atogepant is developed as a preventive migraine treatment.

52

52

pharmaphorum

NOVEMBER 18, 2020

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone.

96

96

The Checkup by Singlecare

DECEMBER 26, 2023

Headaches on the right side of the head can be caused by muscle tension, migraine, sinus inflammation, and more. They can be remedied by over-the-counter (OTC) painkillers, prescription migraine medication, stretching, or hot or cold compresses. Typically, migraine causes throbbing pain on the left or right side of the head.

52

52

pharmaphorum

NOVEMBER 18, 2020

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone.

94

94

PharmaShots

JUNE 1, 2023

Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

40

40

Druggist

JANUARY 9, 2021

Migraine is a common condition affecting an estimated 6 million people in the UK. With approximate 190,000 migraine attacks experienced by people in the UK (NICE, 2012), pharmacies are among the first points of call to find over the counter migraine medication. What is the best painkiller for migraine? Paracetamol.

Packaging 98

Packaging 98

Hospital Pharmacy Europe

SEPTEMBER 8, 2022

Real-world observational study data presented at the Migraine Trust International Symposium (MTIS) demonstrate sustained effectiveness of Ajovy?(fremanezumab) fremanezumab) in reducing migraine attacks. . Fremanezumab is indicated for the prevention of migraine in adults with at least 4 migraine days per month.

Hospitals 52

Hospitals 52

The Checkup by Singlecare

DECEMBER 26, 2023

Eyebrow pain can be associated with various conditions, such as inflamed sinuses or migraine, among others. There are several possible conditions that may cause eyebrow headaches, such as sinusitis , migraine, glaucoma, and more. Migraine Migraine is very common, affecting over 37 million people in the United States.

Immunization 52

Immunization Vaccines 52

pharmaphorum

JULY 18, 2022

AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their recently-approved Vydura drug. GlobalData has said it expects Qulipta to get approval for chronic migraine prevention in 2023, helping it to sales of $1.2

FDA 52

FDA 52

The Checkup by Singlecare

JANUARY 18, 2024

A heavy head may also be due to an illness or medical condition, like a sinus condition or migraine headache. Not sleeping enough —or even sleeping too much to make up for lost sleep—can cause migraines. Then, migraine pain can affect your sleep, causing a cycle of migraine headache pain and interrupted sleep.

Chemotherapy 52

Chemotherapy Hospitals 52